{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:46:15Z","timestamp":1794235575678,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01317-6","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:22:23Z","timestamp":1754497343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Empson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fenili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe Gaetano","family":"Loscocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Klade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-7629","authenticated-orcid":false,"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/bjh.19813","volume":"205","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, et al. Neutrophil\/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy. Br J Haematol. 2024;205:2287\u201394.","journal-title":"Br J Haematol"},{"key":"1317_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387.","journal-title":"Am J Hematol"},{"key":"1317_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","volume":"20","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:1033\u201362.","journal-title":"J Natl Compr Canc Netw"},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u2013e311.","journal-title":"Lancet Haematol"},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian J-J, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30:1018\u201324.","journal-title":"Leukemia"},{"key":"1317_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN. JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934\u201342.","journal-title":"Blood"},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176\u201384.","journal-title":"Blood"},{"key":"1317_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317\u201325.","journal-title":"Nature"},{"key":"1317_CR10","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1182\/bloodadvances.2023010588","volume":"7","author":"MH Kristiansen","year":"2023","unstructured":"Kristiansen MH, Kj\u00e6r L, Skov V, Larsen MK, Ellervik C, Hasselbalch HC, et al. JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study. Blood Adv. 2023;7:5825\u201334.","journal-title":"Blood Adv"},{"key":"1317_CR11","doi-asserted-by":"publisher","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","volume":"10","author":"O Wolach","year":"2018","unstructured":"Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaan8292.","journal-title":"Sci Transl Med"},{"key":"1317_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.2020005407","volume":"137","author":"F Shahneh","year":"2021","unstructured":"Shahneh F, Grill A, Klein M, Frauhammer F, Bopp T, Sch\u00e4fer K, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137:1517\u201326.","journal-title":"Blood"},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519\u201331.","journal-title":"Nat Rev Immunol"},{"key":"1317_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-016-0057-y","volume":"5","author":"M Kovacsovics-Bankowski","year":"2015","unstructured":"Kovacsovics-Bankowski M, Kelley TW, Efimova O, Kim SJ, Wilson A, Swierczek S, et al. Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol. 2015;5:28.","journal-title":"Exp Hematol Oncol"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1038\/s41375-024-02388-3","volume":"38","author":"DC Choi","year":"2024","unstructured":"Choi DC, Messali N, Uda NR, Abu-Zeinah G, Kermani P, Yabut MM, et al. JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms. Leukemia. 2024;38:2487\u201391.","journal-title":"Leukemia"},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ajh.27079","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable \u2018triple A\u2019 risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol. 2023;98:1829\u201337.","journal-title":"Am J Hematol"},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.27261","volume":"99","author":"I Krecak","year":"2024","unstructured":"Krecak I, Lekovic D, Arsenovic I, Holik H, Zekanovic I, Moric Peric M, et al. The triple A model (age, absolute neutrophil count, absolute lymphocyte count-AAA) predicts survival and thrombosis in polycythemia vera. Am J Hematol. 2024;99:989\u201392.","journal-title":"Am J Hematol"},{"key":"1317_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00994-z","volume":"14","author":"MK Larsen","year":"2024","unstructured":"Larsen MK, Skov V, Kj\u00e6r L, Eickhardt-Dalb\u00f8ge CS, Knudsen TA, Kristiansen MH, et al. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study. Blood Cancer J. 2024;14:28.","journal-title":"Blood Cancer J"},{"key":"1317_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","volume":"36","author":"TH N\u00f8st","year":"2021","unstructured":"N\u00f8st TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36:841\u20138.","journal-title":"Eur J Epidemiol"},{"key":"1317_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022;12:28.","journal-title":"Blood Cancer J"},{"key":"1317_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01176-7","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, Ghirardi A, Fenili F, Finazzi MC, Castelli M, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis. Blood Cancer J. 2024;14:195.","journal-title":"Blood Cancer J"},{"key":"1317_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl J Med. 2013;368:22\u201333.","journal-title":"N. Engl J Med"},{"key":"1317_CR23","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8:e175\u2013e184.","journal-title":"Lancet Haematol"},{"key":"1317_CR24","doi-asserted-by":"publisher","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","volume":"2","author":"T Barbui","year":"2023","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2023;2:EVIDoa2200335.","journal-title":"NEJM Evid"},{"key":"1317_CR25","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013e208.","journal-title":"Lancet Haematol"},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/imr.13146","volume":"314","author":"LS Torres","year":"2023","unstructured":"Torres LS, Hidalgo A. Neutrophils as drivers of vascular injury in sickle cell disease. Immunol Rev. 2023;314:302\u201312.","journal-title":"Immunol Rev"},{"key":"1317_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.56875\/2589-0646.1046","volume":"16","author":"S Maharaj","year":"2023","unstructured":"Maharaj S, Chang S. Clinical utility of neutrophil to lymphocyte ratio in sickle cell disease with vaso-occlusive crisis. Hematol Oncol Stem Cell Ther. 2023;16:79\u201382.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1317_CR28","doi-asserted-by":"publisher","first-page":"107602961989511","DOI":"10.1177\/1076029619895111","volume":"26","author":"AM Zahran","year":"2020","unstructured":"Zahran AM, Nafady A, Saad K, Hetta HF, Abdallah A-EM, Abdel-Aziz SM, et al. Effect of hydroxyurea treatment on the inflammatory markers among children with sickle cell disease. Clin Appl Thromb Hemost. 2020;26:1076029619895111.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1317_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.humimm.2015.03.021","volume":"76","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Le Treut T, Baier C, S\u00e9bahoun G, Costello RT. Distribution of lymphocyte subpopulations in patients with polycythemia vera. Hum Immunol. 2015;76:414\u20136.","journal-title":"Hum Immunol"},{"key":"1317_CR30","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3324\/haematol.2020.249441","volume":"106","author":"I Veletic","year":"2021","unstructured":"Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica. 2021;106:2384\u201396.","journal-title":"Haematologica"},{"key":"1317_CR31","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","volume":"18","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Masala G, Antonioli E, Chiara Susini M, Guglielmelli P, Pieri L, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomark Prev. 2009;18:2068\u201373.","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01317-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:03:37Z","timestamp":1757369017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01317-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01317-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TB: Research grant from GSK and AOP. Advisory Board AOP and Italfarmaco. VE and CK are employees of AOP Orphan Pharmaceuticals. GGL: Speaker\u2019s bureau from Novartis and GSK. AI: Speaker honoraria from AOP Health, BMS, GSK, Incyte, Novartis and Pfizer. ER: Advisory Board AOP Health. VDS: Advisory Board AOP Health. PG: Advisory Board Novartis, Incyte and GSK; Speaker\u2019s bureau for Novartis, Gsk, Abbvie, AOP. AMV: Advisory Board and\/or lectures from Novartis, AbbVie, AOP Pharmaceuticals, BMS and Incyte. HG: grants and\/or personal fees from AOP Health, Novartis, and BMS-Pharma. AR: fees for consultancies and participation in meetings, boards, and symposia sponsored by Amgen, Pfizer, Novartis, Kite\u2010Gilead, Jazz, Astellas, Abbvie, Incyte, and Omeros. JMS: Advisory Board or Consultant for Abbvie, Incyte, Protagonist, Novartis, SDP Oncology and Karyopharm. AG, FF, AC and DC have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}